The Central European Biotech Incubator and Accelerator (CEBINA) has announced a partnership with Ursapharm Arzneimittel to repurpose Ursapharm's Pollival azelastine nasal spray for the treatment of COVID-19. In July 2020, CEBINA announced that it had filed a patent application for the use of azelastine to treat COVID-19 and that it was looking for partners … [Read more...] about CEBINA partners with Ursapharm Arzneimittel to develop azelastine nasal spray for the treatment of COVID-19
Business
Windtree gets US patent covering its aerosol delivery system
The US Patent and Trademark Office has issued US Patent No. 10,874,818, titled "Aerosol Delivery System," covering technology used in the delivery of Windtree Therapeutics' Aerosurf aerosolized KL4 surfactant, Windtree said. The company redesigned the aerosol delivery system (ADS) platform prior to initiating Phase 3 studies of Aerosurf after problems with the … [Read more...] about Windtree gets US patent covering its aerosol delivery system
Tonix licenses intranasal oxytocin for the treatment of Prader-Willi syndrome
Tonix Pharmaceuticals announced that it has licensed technology related to oxytocin-based therapies for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from the French National Institute of Health and Medical Research (Inserm). According to Tonix, patents included in the license provide exclusivity through 2031 in the US and Europe. … [Read more...] about Tonix licenses intranasal oxytocin for the treatment of Prader-Willi syndrome
SarcoMed USA acquires worldwide license for Protalix BioTherapeutics’s inhaled alidornase alfa
According to Protalix BioTherapeutics, the company has signed an agreement with SarcoMed USA giving SarcoMed exclusive worldwide license agreement for Protalix's PRX-110 inhaled alidornase alfa for the treatment of respiratory diseases including pulmonary sarcoidosis and pulmonary fibrosis. SarcoMed's lead candidate, SM001, is an inhaled DNase 1 formulation that the … [Read more...] about SarcoMed USA acquires worldwide license for Protalix BioTherapeutics’s inhaled alidornase alfa
Hangzhou Chance Pharmaceuticals gets rights to Aerami’s inhaled imatinib for PAH in the Chinese market
Hangzhou Chance Pharmaceuticals is paying an undisclosed amount up front, plus milestone payments and royalties, to acquire the rights to develop and commercialize Aerami Therapeutics' AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension in China, Hong Kong, Macau, and Taiwan, Aerami has announced. Aerami will continue to develop AER-901 for … [Read more...] about Hangzhou Chance Pharmaceuticals gets rights to Aerami’s inhaled imatinib for PAH in the Chinese market
Herantis partners with Nanoform on intranasal biologics formulation projects
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform's biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics in November 2020. Herantis is developing CDNF for the treatment of Parkinson’s … [Read more...] about Herantis partners with Nanoform on intranasal biologics formulation projects
AuraVax licenses intranasal vaccine technology from University of Houston
AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier this year, the company announced that it had licensed liposomal STING agonist technology from Massachusetts … [Read more...] about AuraVax licenses intranasal vaccine technology from University of Houston
Revelation Biosciences raises $4.4 million for development of REVTx‑99 intranasal PHAD
Revelation Biosciences said that it has closed a private placement financing with gross proceeds of $4.4 million that it plans to use for development of two pipeline products, including its REVTx-99 intranasal phosphorylated hexaacylated disaccharide (PHAD). REVTx-99 is in development for the treatment of viral respiratory infections, including COVID-19. In … [Read more...] about Revelation Biosciences raises $4.4 million for development of REVTx‑99 intranasal PHAD
Noveome partners with Walter Reed Army Institute of Research on preclinical study of intranasal ST266 secretome
Noveome Biotherapeutics has signed a research and development agreement with Walter Reed Army Institute of Research (WRAIR) regarding preclinical studies of an intranasal formulation of Noveome's ST266 secretome, the company said. Under the agreement, WRAIR Branch Chief Deborah Shear will evaluate intranasal ST266 in animal models of traumatic brain injury (TBI), with … [Read more...] about Noveome partners with Walter Reed Army Institute of Research on preclinical study of intranasal ST266 secretome
US Department of Defense provides up to $6 million for Phase 2 trials of PUL-042 inhalation solution for the treatment of COVID-19
According to Pulmotect, the US Department of Defense has provided a grant worth up to $6 million for the completion of two Phase-2 clinical trials of the company's PUL-042 immunostimulant inhalation solution for the prevention and treatment of COVID-19. In May 2020, Pulmotect announced that it had gotten FDA permission for the two trials. The studies, which both … [Read more...] about US Department of Defense provides up to $6 million for Phase 2 trials of PUL-042 inhalation solution for the treatment of COVID-19